Jason Westin

Jason Westin is a DLBCL clinical investigator who co-led the TRANSFORM trial demonstrating superior outcomes with lisocabtagene maraleucel (liso-cel) versus salvage chemotherapy plus autologous stem cell transplant in second-line relapsed/refractory DLBCL. This work, alongside ZUMA-7, established CAR-T cell therapy as the new standard of care for early relapsed DLBCL. He investigates patient selection for CAR-T versus bispecific antibodies, access barriers, and DLBCL management in frail elderly patients. He leads the MD Anderson lymphoma clinical trials portfolio.